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The World Health Organization (WHO) classification recognizes 2 main categories of natural killer (NK) cell-derived neoplasms,
namely, extranodal NK/T-cell lymphoma, nasal type, and aggressive NK-cell leukaemia. Extranodal nasal NK/T-cell lymphoma is
more frequent in the Far East and Latin America. Histopathological and immunophenotypical hallmarks include angiocentricity,
angiodestruction, expression of cytoplasmic CD3 epsilon (ε), CD56, and cytotoxic molecules and evidence of Epstein-Barr
virus (EBV) infection. Early stage disease, in particular for localized lesion in the nasal region, is treated with chemotherapy
and involved-field radiotherapy. On the other hand, multiagent chemotherapy is the mainstay of treatment for advanced or
disseminated disease. L-asparaginase-containing regimens have shown promise in treating this condition. The role of autologous
hematopoietic stem cell transplantation is yet to be clearly defined. Allogeneic hematopoietic stem cell transplantation, with the
putative graft-versus-lymphoma eﬀect, oﬀers a potentially curative option in patients with advanced disease.
1. Introduction
Natural killer (NK) cells are lymphoid cells that mediate lysis
of tumor cells and bacteria- or virus-infected cells and the
production of immunomodulatory cytokines [1]. Morpho-
logically, mature NK cells are large granular lymphoid cells,
which are characterized by the presence of pale cytoplasm
containing azurophilic granules. Unlike T-cell large granular
lymphocytes, they are negative for surface CD3 but charac-
teristically express cytoplasmic CD3 epsilon (ε), CD56, and
cytotoxic molecules. Furthermore, clonal rearrangement of
the T cell receptor (TCR) genes is also absent in NK cells.
The latest World Health Organization (WHO) classification
recognizes 2 main categories of NK cell-derived neoplasms,
namely, aggressive NK cell leukemia and extranodal NK/T-
cell lymphoma, nasal type [2, 3]. Evidence of Epstein-Barr
virus (EBV) infection in the lymphoma cells is a consistent
finding which may be directly involved in lymphomagenesis
[4–6]. NK/T-cell lymphoma of the nasal type has a distinctive
ethnic and geographical distribution, accounting for 7% to
10% of all non-Hodgkin lymphomas in Asia and Latin Amer-
ica, but only 1% of that amongst Caucasians [7–9]. On the
other hand, aggressive NK-cell leukaemia, which is consid-
ered as the leukaemic counterpart of NK/T-cell lymphoma,
is an uncommon disease. The rest of this paper will focus the
discussion on NK/T-cell lymphoma of the nasal type.
2. Histopathology
NK/T-cell lymphoma shows an angiocentric and angi-
odestructive pattern of growth with associated geographical
necrosis and ulceration. Coagulative necrosis and apoptotic
bodies are frequently encountered. The tumor cells are small
to medium in size with occasional large and anaplastic forms
(Figure 1(a)). The lymphoma cells may be admixed with
a polymorphic infiltrate of nonneoplastic inflammatory
cells including small lymphocytes, plasma cells, histiocytes,
and eosinophils. The immunophenotype of NK lymphoma
cells is classically positive for CD2, CD56, and cytoplasmic
CD3 epsilon (ε). They are negative for surface CD3. Unlike
normal NK cells, the tumor cells are usually negative for
CD7 and CD16. They express cytotoxic granule associated
proteins granzyme B, T-cell restricted intracellular antigen
(TIA-1), and perforin. Presence of EBV infection shown
by in situ hybridization (ISH) for EBV-encoded early small
RNA (EBER) is a distinctive feature (Figure 1(b)). The
World Health Organization classification requires both
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Figure 1: (a) Histology of NK/T-cell lymphoma showing presence of atypical lymphoid cells, which aremedium to large in size with irregular
and hyperchromatic nuclei. (b) In situ hybridization for Epstein Barr virus-encoded early RNAs (EBER) positivity in NK/T-cell lymphoma.
(c) NK/T-cell lymphoma of the nasal type presenting with perforation of hard palate. (d) PET/CT scan of a patient with NK/T-cell lymphoma
showing a FDG-avid mass in the right nasal cavity.
EBV positivity and expression of cytotoxic granules for
the diagnosis of NK/T-cell lymphoma, nasal-type [2].
EBV positive NK/T lymphomas with typical clinical and
morphological features and expression of cytotoxic granules
can be classified as such even if they deviate from the classical
immunophenotype, for instance, CD8 positivity or CD56
negativity [10]. The classification of EBV negative tumors
with expression of cytotoxic proteins remains controversial.
Occasional neoplastic cells can express CD30 with large cell
morphology simulating anaplastic large cell lymphoma [10].
Aberrant expression of the B-cell marker CD20 has been
described in 3 cases to date but the significance of which
remains uncertain [10–12].
3. Clinical Features
NK/T-cell lymphomas have a distinctive geographical dis-
tribution with most cases being reported in Asia and
Latin America. Clinically, it is useful to classify NK/T-
cell malignancies into two categories, namely, nasal NK-
cell lymphomas, and nonnasal or extranasal NK/T-cell
lymphomas, depending on the site of the lesions [13].
Nasal NK/T-cell lymphomas occur in the nose and the
upper aerodigestive tract. Males predominate and they
usually present in their fifties. Common sites of involve-
ment include the nasal cavity, nasopharynx, paranasal
sinuses, hypopharynx, and larynx [10, 13]. As a result, the
common presenting symptoms include nasal obstruction,
epistaxis, and facial swelling. Retro-orbital involvement
causes proptosis and impairment of extraocular movement.
Occasionally local extension from the nasal cavity causes
destruction of the hard palate with the characteristic mid-
line perforation, previously referred to as “lethal midline
granuloma” (Figure 1(c)). Bone marrow involvement occurs
in less than 10% of patients and distant metastasis is
unusual.
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Extranasal or nonnasal NK/T-cell lymphomas likewise
are more prevalent in males in their fifth decade. As its
name implies, it occurs outside the typical nasal region,
and the common primary sites involved include the skin,
gastrointestinal tract, salivary glands, spleen, and testis.
Unusual sites of involvement such as the muscle, the adrenal
gland, and the female genital tract (ovaries and uterus) have
been reported [10]. Distant dissemination occurs early in
the clinical course of the disease. Many extranasal NK/T-cell
lymphomas might represent disseminated nasal NK/T-cell
lymphomas, particularly when the primary sites of extranasal
NK-cell lymphomas are precisely the sites where nasal NK/T-
cell lymphomas will metastasize to. Occult nasal involvement
should therefore be carefully evaluated by flexible nasal
panendoscopy with multiple random biopsies in patients
presenting with extranasal NK/T-cell lymphoma. In both
nasal and nonnasal NK/T-cell lymphomas, isolated nodal
involvement is highly unusual [10, 13].
4. Staging
A standard staging system for NK/T-cell lymphomas is
lacking. As for other extranodal lymphomas, the Ann-Arbor
staging system, originally designed for Hodgkin’s lymphoma,
is unsatisfactory for NK/T-cell lymphomas [14]. It does not
take into account the tumor size and the resultant invasion to
contiguous structures whichmay be an important prognostic
determinant. A T-staging system, originally designed for
sinonasal B-cell lymphoma has been adopted to overcome
this problem by taking into account the extent of local
tumor involvement [15]. T1 denotes confinement to the
nasal cavity. T2 indicates extension to the maxillary antra,
anterior ethmoid sinus or hard palate. T3 indicates extension
to posterior ethmoid sinus, sphenoidal sinus, orbit, superior
alveolar bone, cheeks, or superior buccinators space. T4
indicates involvement of the inferior alveolar bone, inferior
buccinators space, infratemporal fossa, nasopharynx, or
cranial fossa. Patients with T1/2 disease had shown a better
clinical outcome than those with T3/4 disease [16].
5. Imaging Assessment
Computerized tomography (CT) has been conventionally
utilized to assess the local extent of the disease as well
distant metastases. Magnetic resonance imaging (MRI) has
been shown to better define local soft tissue and bony
involvement. The use of Fluorine-18 fluorodeoxyglucose
positron emission tomography computerized tomography
(18-FDG PET-CT) has been evaluated (Figure 1(d)). NK-cell
lymphomas were shown to be FDG-avid and PET-CT oﬀers
more accurate definition of the extent of involvement by
distinguishing lymphoma involvement from inflammatory
masses [17]. This has important implications in radiotherapy
planning. PET, however, may not detect morphologically
occult marrow infiltration uncovered by ISH for EBER [17].
In a recent retrospective analysis of 117 patients with non-
Hodgkin lymphomas, the highest maximum standard uptake
value (SUVmax) of NK-cell lymphoma was 9.2± 4.5 which is
significantly lower than that of aggressive B-cell lymphomas
but high than that of indolent B-cell lymphomas [18]. 18-
FDG PET-CT is increasingly used both at diagnosis and for
monitoring of response to therapy.
6. Quantification of Plasma EBV DNA Level
Apoptosis of proliferating EBV-related tumor cells releases
EBV DNA into the circulation [19]. Quantification of cir-
culating plasma EBV DNA level by quantitative polymerase
chain reaction (PCR) is used as a surrogate marker of tumor
burden and has been shown to correlate with disease status
in patients with NK/T-cell lymphomas. A high level of
circulating plasma EBV DNA has correlated with high tumor
load, extensive disease, poorer response to treatment, and
inferior survival [20].
7. Prognostic Factors
The International Prognostic Index (IPI) predicts outcome in
nasal NK/T-cell lymphoma. Patients with IPI of 1 or less were
shown to have a better overall survival [13, 14]. In a recent
retrospective analysis of 172 patients with extranodal NK/T-
cell lymphoma, nasal type, and aggressive NK-cell leukemia,
4 prognostic factors were identified. These include nonnasal
type, stage, performance status, and number of extranodal
sites [21]. Level of circulating plasma EBV DNA at pre-
sentation has been shown to significantly aﬀect disease-free
survival [13, 14, 20]. Finally, a prognostic model based on a
retrospective analysis of 262 patients has been proposed by
Korean investigators [22]. In this Korean prognostic model,
four prognostic groups have been identified depending on B-
symptoms, stage, LDH level, and regional lymphadenopathy.
8. Treatment of Localized Disease
Because of the low incidence of NK/T-cell malignancies,
randomized control trials on treatment have not been
available. Most treatment protocols are instead consensus
based and are derived from retrospective and small prospec-
tive studies. The prognosis of nasal NK/T-cell lymphomas
has gradually improved with modern treatment protocols
combining chemotherapy and radiotherapy. On the other
hand, prognosis remains guarded in most extranasal and
disseminated cases.
For stage I/II nasal NK/T-cell lymphomas, radiotherapy
is an important modality of treatment. Nonnasal NK cell
lymphomas tend to have advanced or disseminated disease
at presentation and the role of radiotherapy is often limited.
The reported overall response rate of localized nasal disease
after radiotherapy ranged from 60% to 80% with a complete
remission (CR) rate of 40% 80% and a 5-year overall survival
(OS) of 40 to 59% [13, 14]. Careful planning with the
assistance of modern imaging modalities like CT and MRI is
required before radiotherapy. A total radiotherapy dose of 30
to 60Gy with fractional doses of 1.5 to 2.5Gy is typically used
[14]. Despite the excellent initial response to radiotherapy
alone, a high relapse rate of around 50% is reported. Local
failure, including in-field and margin failures, usually occur
within 1 year and is associated with a radiotherapy dose of
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less than 45 to 50Gy and radiotherapy planning not assisted
by imaging [23]. Local relapses beyond 2 years are uncom-
mon although late relapses have been reported [23, 24].
Systemic relapses occur in 25% to 30% of cases, more than
half of which is not associated with local recurrences [13]. In
light of the high relapse rate with radiotherapy alone, com-
bination of chemotherapy and radiotherapy is the current
standard of care in patients who can tolerate systemic treat-
ment. A commonly used anthracycline-containing regime
is CHOP (cyclophosphamide, doxorubicin, vincristine, and
prednisolone). Primary chemotherapy for stage I/II nasal
NK/T-cell lymphomas yields a CR rate of around 40% to
60%. Nevertheless, a high rate of disease progression (30–
40%) and relapse after initial CR (30–40%) is observed [13,
14]. The expression of multidrug resistance (MDR) gene and
high levels of P-glycoprotein in NK lymphoma cells underlies
the resistance to anthracyclines and vinca alkaloids [25].
Regimens bases on non-P glycoprotein eﬄux chemother-
apeutic agents such as L-asparaginase, ifosphamide, and
methotrexate may potentially improve response rates. The
optimal dose, combination and sequence of radiotherapy
and chemotherapy remain to be defined though the current
trend is to provide involved field radiotherapy after an
initial three courses of chemotherapy. Concurrent chemora-
diotherapy has been studied in two recent phase II trials
with favorable results [26, 27]. In our center, for patients
with stage I/II disease, the standard is to oﬀer multiagent
chemotherapy using the regimen SMILE (dexamethasone,
methotrexate with leucovorin, ifosfamide, L-asparaginase,
and etoposide). A total of six courses of chemotherapy
is oﬀered. Involved-field radiation is administered after 3
courses of chemotherapy.
9. Treatment of Disseminated Disease
For the stage III/IV nasal NK/T-cell lymphomas, extran-asal
NK/T-cell lymphomas and aggressive NK-cell lymphoma/
leukemia, chemotherapy is the primary treatment [13, 14].
Results from chemotherapy adopted from treating aggressive
B-cell lymphomas such as CHOP is far from satisfactory
[14]. L-asparaginase-containing regimens have shown
promise. As mentioned early, L-asparaginase is not aﬀected
by P-glycoprotein. Furthermore, the tumor cells lack L-
asparagine synthetase and are susceptible to L-asparaginase
which depletes L-asparagines in NK lymphoma cells [14].
A retrospective analysis of Chinese patients with relapsed
or refractory NK/T-cell lymphoma, nasal type yielded an
overall response rate of 82% and a CR rate of 56%. The
5-year survival reported in that series was 67% [28]. The
protocol SMILE (consisting Steroids, Methotrexate and
folinic acid, Ifosfamide, L-asparaginase, and Etoposide) was
studied in treating patients with relapsed and refractory
disease. Prophylactic use of granulocyte colony-stimulating
factor (G-CSF) was necessary due to significant marrow
suppression. The overall response rate was 67% with a CR
rate of 50% [29]. In our center, patients with advanced-stage
disease are treated with 6 courses of SMILE chemotherapy
regime. Allogeneic hematopoietic stem cell transplantation
is also considered for suitable candidates (see below).
10. Role of Hematopoietic Stem Cell
Transplantation (HSCT)
The unsatisfactory treatment outcome for advanced and
disseminated NK/T-cell lymphoma has led to the use
of high-dose chemotherapy and hematopoietic stem cell
transplantation. Autologous HSCT has been evaluated in
stage I/II disease in first or second complete remission, or
chemosensitive relapse, and primary or secondary refractory
disease without marrow involvement [13]. The disease status
pre-HSCT significantly aﬀected overall survival and patients
with refractory disease had a significantly inferior survival
after autologous HSCT [30]. As most patients with stage
I/II disease would be expected to have durable remissions
following multiagent chemotherapy and radiotherapy, the
definite advantage of autologous HSCT in first complete
remission (CR1) is questionable. However, based on a
retrospective analysis on a small group of patients, there
was evidence that autologous HSCT may be beneficial in
a subgroup of patients in CR1 who have a high risk of
relapse as determined by prognostic modeling [31]. HSCT is
generally indicated in lymphoma patients achieving second
complete remission (CR2) though further controlled trials
are required to examine whether this also applies to NK/T-
cell lymphoma. There is no survival advantage of autologous
HSCT in patients with advanced or refractory disease [30].
Allogeneic HSCT, with the potential benefit of graft-versus-
lymphoma (GVL) eﬀect, is a sound option for patients with
advanced disease. The GVL eﬀect is further enhanced by
the expression of EBV antigen on tumor cells, providing
an alloreactive target [14]. Small series have shown that
it is a potentially curative option [32]. In our centre,
allogeneic haematopoietic stem cell transplantation is oﬀered
to selected cases with advanced stage disease who achieve
complete remission after 6 courses of SMILE chemotherapy.
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